Scholarlink

Background <p>Adverse reactions to vaccines are common, but the nature and severity vary among individuals. This study describes vaccine reactions following vaccination with the coronavirus disease 2019 (COVID-19) mRNA vaccine Comirnaty® (Bretovameran, BioNTech Manufacturing, Mainz, Germany) and the vector-based vaccine Vaxzevria® (ChAdOx1‑S, AstraZeneca, Cambridge, UK). Particular focus was placed on the pattern of reactions in individuals with and without allergies or atopic diseases. Furthermore, the study investigated whether gender- or age-specific differences were discernible.</p> Hypothesis <p>The type and frequency of immunogenic vaccine reactions differ depending on individual, potentially predisposing factors such as pre-existing allergies, atopic status, or age and gender.</p> Methods <p>Employees who received their first vaccination with the Comirnaty® or Vaxzevria® vaccines from the occupational health service of the University Hospital Marburg during the COVID-19 pandemic between December&#xa0;27, 2020, and April&#xa0;23, 2021 were given an anonymous questionnaire. Information was obtained regarding the occurrence of immunogenic and allergic vaccine reactions, as well as age, gender, known allergies, and pre-existing atopic conditions.</p> Results <p>In all, 74.8% of vaccinated employees (<i>n</i> = 2845) participated in the study. Both COVID-19 vaccines administered showed a&#xa0;high incidence (70.6%) of local reactions and a&#xa0;comparatively lower frequency of systemic immune reactions such as fatigue (45.6%), headaches (35.1%), and muscle aches (27.1%). The most common side effects were pain at the injection site, fatigue, headaches, muscle aches, and joint pain. Individuals with a&#xa0;history of allergies and/or atopic diseases developed immunogenic local or systemic reactions significantly more frequently. Female and younger people (aged&#xa0;18–34) were more likely to develop systemic reactions, while male participants were more likely to experience local vaccine side effects. No life-threatening side effects, particularly no anaphylaxis, were observed in connection with the vaccination.</p> Conclusion <p>Individuals with allergies and atopic conditions appear to notice immunogenic reactions more frequently following vaccination. Possible reasons could include a&#xa0;specific immunoreactive predisposition or subjective expectations. The pattern of vaccine reactions may vary by gender and age.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Individuals with a history of allergic disease experience immunogenic side effects of vaccination more frequently

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Valeria Hernández Guerrero,
  • Julia Kurz,
  • Urte Joseph,
  • Christian Möbs,
  • Oliver Pfaar,
  • Georgios Chatzis,
  • Wolfgang Pfützner

摘要

Background

Adverse reactions to vaccines are common, but the nature and severity vary among individuals. This study describes vaccine reactions following vaccination with the coronavirus disease 2019 (COVID-19) mRNA vaccine Comirnaty® (Bretovameran, BioNTech Manufacturing, Mainz, Germany) and the vector-based vaccine Vaxzevria® (ChAdOx1‑S, AstraZeneca, Cambridge, UK). Particular focus was placed on the pattern of reactions in individuals with and without allergies or atopic diseases. Furthermore, the study investigated whether gender- or age-specific differences were discernible.

Hypothesis

The type and frequency of immunogenic vaccine reactions differ depending on individual, potentially predisposing factors such as pre-existing allergies, atopic status, or age and gender.

Methods

Employees who received their first vaccination with the Comirnaty® or Vaxzevria® vaccines from the occupational health service of the University Hospital Marburg during the COVID-19 pandemic between December 27, 2020, and April 23, 2021 were given an anonymous questionnaire. Information was obtained regarding the occurrence of immunogenic and allergic vaccine reactions, as well as age, gender, known allergies, and pre-existing atopic conditions.

Results

In all, 74.8% of vaccinated employees (n = 2845) participated in the study. Both COVID-19 vaccines administered showed a high incidence (70.6%) of local reactions and a comparatively lower frequency of systemic immune reactions such as fatigue (45.6%), headaches (35.1%), and muscle aches (27.1%). The most common side effects were pain at the injection site, fatigue, headaches, muscle aches, and joint pain. Individuals with a history of allergies and/or atopic diseases developed immunogenic local or systemic reactions significantly more frequently. Female and younger people (aged 18–34) were more likely to develop systemic reactions, while male participants were more likely to experience local vaccine side effects. No life-threatening side effects, particularly no anaphylaxis, were observed in connection with the vaccination.

Conclusion

Individuals with allergies and atopic conditions appear to notice immunogenic reactions more frequently following vaccination. Possible reasons could include a specific immunoreactive predisposition or subjective expectations. The pattern of vaccine reactions may vary by gender and age.